Lv1
46 积分 2024-08-19 加入
Materials for oral delivery of proteins and peptides
2天前
已完结
Oral Muvalaplin for Lowering of Lipoprotein(a)
8天前
已完结
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
14天前
已完结
Evaluating Scale-Up Rules of a High-Shear Wet Granulation Process
1个月前
已完结
FDA approved PFS-based autoinjectors: evolution, market trends, and development challenges
1个月前
已完结
Strategies for Accelerated Drug Development: An Industry Perspective Based on an IQ Consortium Survey of CMC Considerations
1个月前
已完结
Characterization of adsorption behavior by solid dosage form excipients in formulation development
2个月前
已完结
Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
2个月前
已完结
Impurity Qualification Thresholds: An IQ Survey on Emerging Industry Experience with Health Authority Feedback
3个月前
已完结
Solid dispersion technology as a formulation strategy for the fabrication of modified release dosage forms: A comprehensive review
7个月前
已完结
皖公网安备34019202002308
